Search results
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 19 hours agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 1 day agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 3 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 22 hours agoOn Monday, Deutsche Bank reiterated a Hold rating and a price target of GBP110.00 on stock of ...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
Motley Fool via Yahoo Finance· 7 days agoAstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 4 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 11 hours agoThe conference was a big one for Summit Therapeutics, which saw its stock price more than double...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
AstraZeneca (NASDAQ:AZN) Now Covered by Analysts at The Goldman Sachs Group
ETF DAILY NEWS· 6 days agoThe Goldman Sachs Group assumed coverage on shares of AstraZeneca (NASDAQ:AZN – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings ...
AstraZeneca shares target raised by Argus on new drug approvals By Investing.com
Investing.com· 7 days agoThe new price target is set at $85.00, up from the previous $80.00, while the firm continues to...